187 related articles for article (PubMed ID: 16838648)
1. [Interferon -beta therapy in multiple sclerosis].
Satoh J
Nihon Rinsho; 2006 Jul; 64(7):1297-309. PubMed ID: 16838648
[TBL] [Abstract][Full Text] [Related]
2. T cell gene expression profiling identifies distinct subgroups of Japanese multiple sclerosis patients.
Satoh J; Nakanishi M; Koike F; Onoue H; Aranami T; Yamamoto T; Kawai M; Kikuchi S; Nomura K; Yokoyama K; Ota K; Saito T; Ohta M; Miyake S; Kanda T; Fukazawa T; Yamamura T
J Neuroimmunol; 2006 May; 174(1-2):108-18. PubMed ID: 16564577
[TBL] [Abstract][Full Text] [Related]
3. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
[TBL] [Abstract][Full Text] [Related]
4. CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance. The role of IFNbeta-1a in the treatment of multiple sclerosis.
Pellegrini P; Totaro R; Contasta I; Berghella AM; Carolei A; Adorno D
Neuroimmunomodulation; 2005; 12(4):220-34. PubMed ID: 15990453
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.
Byun E; Caillier SJ; Montalban X; Villoslada P; Fernández O; Brassat D; Comabella M; Wang J; Barcellos LF; Baranzini SE; Oksenberg JR
Arch Neurol; 2008 Mar; 65(3):337-44. PubMed ID: 18195134
[TBL] [Abstract][Full Text] [Related]
6. Beta-interferon unbalances the peripheral T cell proinflammatory response in experimental autoimmune encephalomyelitis.
Martín-Saavedra FM; Flores N; Dorado B; Eguiluz C; Bravo B; García-Merino A; Ballester S
Mol Immunol; 2007 Jul; 44(14):3597-607. PubMed ID: 17420051
[TBL] [Abstract][Full Text] [Related]
7. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
Hesse D; Sellebjerg F; Sorensen PS
Neurology; 2009 Aug; 73(5):372-7. PubMed ID: 19652141
[TBL] [Abstract][Full Text] [Related]
8. Implication of the Toll-like receptor 4 pathway in the response to interferon-β in multiple sclerosis.
Bustamante MF; Fissolo N; Río J; Espejo C; Costa C; Mansilla MJ; Lizasoain I; Moro MA; Carmen Edo M; Montalban X; Comabella M
Ann Neurol; 2011 Oct; 70(4):634-45. PubMed ID: 22028223
[TBL] [Abstract][Full Text] [Related]
9. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
[TBL] [Abstract][Full Text] [Related]
10. Interferon-beta mechanisms of action in multiple sclerosis.
Dhib-Jalbut S; Marks S
Neurology; 2010 Jan; 74 Suppl 1():S17-24. PubMed ID: 20038758
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis.
Sriram U; Barcellos LF; Villoslada P; Rio J; Baranzini SE; Caillier S; Stillman A; Hauser SL; Montalban X; Oksenberg JR
Genes Immun; 2003 Mar; 4(2):147-52. PubMed ID: 12618863
[TBL] [Abstract][Full Text] [Related]
12. [Molecular biomarkers for prediction of multiple sclerosis relapse].
Satoh J
Nihon Rinsho; 2008 Jun; 66(6):1103-11. PubMed ID: 18540355
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis.
Hong J; Zang YC; Hutton G; Rivera VM; Zhang JZ
J Neuroimmunol; 2004 Jul; 152(1-2):126-39. PubMed ID: 15223245
[TBL] [Abstract][Full Text] [Related]
14. Effects of interferon-beta on microglial functions as inflammatory and antigen presenting cells in the central nervous system.
Kawanokuchi J; Mizuno T; Kato H; Mitsuma N; Suzumura A
Neuropharmacology; 2004 Apr; 46(5):734-42. PubMed ID: 14996551
[TBL] [Abstract][Full Text] [Related]
15. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
[TBL] [Abstract][Full Text] [Related]
16. [Interferon-beta treatment for multiple sclerosis and predictors of response].
Kohriyama T; Ochi K; Matsumoto M
Nihon Rinsho; 2008 Jun; 66(6):1119-26. PubMed ID: 18540357
[TBL] [Abstract][Full Text] [Related]
17. Biologic role of interferon beta in multiple sclerosis.
Billiau A; Kieseier BC; Hartung HP
J Neurol; 2004 Jun; 251 Suppl 2():II10-4. PubMed ID: 15264107
[TBL] [Abstract][Full Text] [Related]
18. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M
J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872
[TBL] [Abstract][Full Text] [Related]
19. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
Pachner AR; Cadavid D; Wolansky L; Skurnick J
Neurology; 2009 Nov; 73(18):1485-92. PubMed ID: 19884576
[TBL] [Abstract][Full Text] [Related]
20. Innate immunity modulates autoimmunity: type 1 interferon-beta treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation.
Gigli G; Caielli S; Cutuli D; Falcone M
Immunology; 2007 Nov; 122(3):409-17. PubMed ID: 17617156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
